TY - JOUR
T1 - Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation
AU - De La Cruz-Herrera, C. F.
AU - Baz-Martínez, M.
AU - Lang, V.
AU - El Motiam, A.
AU - Barbazán, J.
AU - Couceiro, R.
AU - Abal, M.
AU - Vidal, A.
AU - Esteban, M.
AU - Muñoz-Fontela, C.
AU - Nieto, A.
AU - Rodríguez, M. S.
AU - Collado, M.
AU - Rivas, C.
N1 - Publisher Copyright:
© 2016 Macmillan Publishers Limited.
PY - 2016/6/2
Y1 - 2016/6/2
N2 - Class IA phosphatidylinositol 3-kinases (PI3Ks) are composed of p110 catalytic and p85 regulatory subunits. How regulatory subunits modulate PI3K activity remains only partially understood. Here we identified SUMO (small ubiquitin-related modifier) as a new player modulating this regulation. We demonstrate that both p85β and p85α are conjugated to SUMO1 and SUMO2. We identified two lysine residues located at the inter-SH2 domain on p85β, a critical region required for inhibition of p110, as being required for SUMO conjugation. A SUMOylation-defective mutant p85β shows higher activation of the PI3K pathway, and increased cell migration and transformation. Moreover, the cancer-related KS459del mutant in p85α was less efficiently SUMOylated compared with the wild-type protein. Finally, our results show that SUMO modulates p85 tyrosine phosphorylation, a modification correlating with PI3K pathway activation. Thus, SUMO reduces the levels of tyrosine-phosphorylated-p85 while loss of SUMOylation results in increased tyrosine phosphorylation of p85. In summary, we identify SUMO as a new important player in the regulation of the PI3K pathway through modulation of p85.
AB - Class IA phosphatidylinositol 3-kinases (PI3Ks) are composed of p110 catalytic and p85 regulatory subunits. How regulatory subunits modulate PI3K activity remains only partially understood. Here we identified SUMO (small ubiquitin-related modifier) as a new player modulating this regulation. We demonstrate that both p85β and p85α are conjugated to SUMO1 and SUMO2. We identified two lysine residues located at the inter-SH2 domain on p85β, a critical region required for inhibition of p110, as being required for SUMO conjugation. A SUMOylation-defective mutant p85β shows higher activation of the PI3K pathway, and increased cell migration and transformation. Moreover, the cancer-related KS459del mutant in p85α was less efficiently SUMOylated compared with the wild-type protein. Finally, our results show that SUMO modulates p85 tyrosine phosphorylation, a modification correlating with PI3K pathway activation. Thus, SUMO reduces the levels of tyrosine-phosphorylated-p85 while loss of SUMOylation results in increased tyrosine phosphorylation of p85. In summary, we identify SUMO as a new important player in the regulation of the PI3K pathway through modulation of p85.
UR - http://www.scopus.com/inward/record.url?scp=84973352753&partnerID=8YFLogxK
U2 - 10.1038/onc.2015.356
DO - 10.1038/onc.2015.356
M3 - Article
C2 - 26411363
AN - SCOPUS:84973352753
SN - 0950-9232
VL - 35
SP - 2873
EP - 2880
JO - Oncogene
JF - Oncogene
IS - 22
ER -